Treatment patterns and prognosis in patients with Bacillus Calmette–Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis-Reference-Cited by-同舟云学术

Treatment patterns and prognosis in patients with Bacillus Calmette–Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis

Published:2024-03-21 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Nishimura Nobutaka,Miyake Makito^ORCID,Iida Kota,Miyamoto Tatsuki,Tomida Ryotaro,Numakura Kazuyuki,Inokuchi Junichi,Yoneyama Takahiro,Okajima Eijiro,Yajima Shugo,Masuda Hitoshi,Terada Naoki,Taoka Rikiya,Kobayashi Takashi,Kojima Takahiro,Matsui Yoshiyuki,Nishiyama Naotaka,Kitamura Hiroshi,Nishiyama Hiroyuki,Fujimoto Kiyohide

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-04834-4.pdf

Reference17 articles.

1. Babjuk M, Burger M, Capoun O et al (2022) European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:75–94

2. Matsumoto H, Shiraishi K, Azuma H et al (2020) Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27:702–709

3. Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines® Insights: bladder cancer, Version 2.2022. J Natl Compr Cancer Netw. 20:866–878

4. Chang SS, Boorjian SA, Chou R (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 196:1021–1029

5. Kamat AM, Sylvester RJ, Bohle A et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 34:1935–1944